ArticleWorld journal of gastroenterology2026
Synergistic anti-hepatoma effect of triptolide and quercetin
Article in World journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver carcinoma, as a major global health concern due to its high incidence and mortality rates. Despite advancements in diagnostic and treatment methodologies, outcomes for hepatocellular carcinoma remain unsatisfactory. In response to these limitations, patients increasingly turn to alternative therapies such as traditional Chinese medicine, which has demonstrated potential in enhancing quality of life and prolonging survival in combination with conventional treatments. Triptolide (TP) and quercetin, as two broad-spectrum antitumor activities, act through multiple mechanisms, and whether the combination of them can provide a synergistic effect to improve the treatment effect. To optimize the dosage combination of TP and quercetin to maximize their therapeutic benefits in treating liver cancer, potentially advancing the field of drug combination therapy. This approach seeks to explore new treatment strategies and elucidate the underlying mechanisms that could lead to improved outcomes for hepatocellular carcinoma patients facing limited effective treatment options.
aimTo investigate the synergistic anti-hepatoma effect of TP and quercetin and elucidate the underlying molecular mechanism involving the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and mammalian target of rapamycin (mTOR) signaling pathways.
methodsThe study utilized 5-week-old female BALB/c-nu mice for establishing a liver cancer subcutaneous transplant tumor model. TP and quercetin were administered intraperitoneally over 21 days to evaluate the effectiveness of the combination, with monitoring of tumor growth. IncuCyte Zoom and CompuSyn software were employed to analyze drug effects for different dose combination on cell proliferation and synergy. Various assays such as CCK-8 cell proliferation analysis, plate cell clone formation, cell scratch experiments, Transwell migration and invasion assays, Annexin V-FITC flow cytometry, and western blotting using specific antibodies were employed to assess cell apoptosis, migration, invasion. Then transcriptome analysis was used RNA sequencing to find the potential synergistic mechanisms and proved by western blotting.
results
conclusionCompared with a single drug, the specific metering combination of TP and quercetin has enhanced anti-tumor effects, mediated by inhibition of cell proliferation, inducing cell apoptosis and inhibiting migration/invasion. This synergistic effect is closely related to the simultaneous inhibition of signaling pathways JAK-STAT and mTOR concurrently.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.